Loading patent…
AssigneeBristol-Myers Squibb Company
InventorsNils Lonberg, Mohan Srinivasan
Estimating the term…
The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
A method for inhibiting growth of tumor cells in a subject comprising administering to the subject an antibody comprising heavy and light chain variable regions that bind human LAG-3, wherein the heavy chain CDR1, CDR2, and CDR3 regions comprise the amino acid sequences of SEQ ID NOs:
A method of treating cancer in a subject in need thereof comprising administering to the subject an antibody that binds human LAG-3, wherein the heavy chain CDR1, CDR2, and CDR3 regions comprise the amino acid sequences of SEQ ID NOs:
A method of treating cancer in a subject in need thereof comprising administering to the subject a full-length IgG4 human monoclonal antibody that binds human LAG-3, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:
A method of treating cancer in a subject in need thereof comprising administering to the subject
Dependencies are inferred from the claim text.